Skip to content

MBX Biosciences, Inc. MBX Vesting Of Early Exercised Stock Options

Other financials

Income statement

See full
Operating income-$27.3M-2.8%
Net income-$23.5M+1.5%
EPS (diluted)-$0.50+29.6%

Balance sheet

See full
Cash & equivalents$45.2M+51.2%
Total debt$555.0K+327%
Total equity$437.8M+85.9%
Total assets$452.7M+84.1%

Cash flow

See full
Operating cash flow-$20.2M+10.9%
CapEx$437.0K+1,357%
Free cash flow-$20.6M+9.1%

Valuation

See full
Market cap$2.3B+475%
Enterprise value$2.26B+533%

Returns & leverage

See full
Return on equity-25.7%
Debt / equity0.0×
Current ratio30.8×+7.5×

Where this comes from

Reported directly by MBX Biosciences, Inc. in its filing.

Tagged under the XBRL concept mbx:VestingOfEarlyExercisedStockOptions.

The official record: MBX Biosciences, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about MBX Biosciences, Inc.'s vesting of early exercised stock options.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MBX Biosciences, Inc.'s vesting of early exercised stock options?
MBX Biosciences, Inc. (MBX) reported vesting of early exercised stock options of $2K in Q1 2026.
How has MBX Biosciences, Inc.'s vesting of early exercised stock options changed year-over-year?
MBX Biosciences, Inc.'s vesting of early exercised stock options decreased by 89.5% year-over-year, from $19K to $2K.